We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




DPC Granted License to Develop Cancer Diagnostics

By HospiMedica staff writers
Posted on 28 Jan 2003
A license to develop and commercialize diagnostic assays based on two novel prostate-specific proteins for detecting and monitoring prostate cancer and perhaps other cancers has been granted to Diagnostic Products Corp. More...
(Los Angeles, CA, USA) by Compugen, Ltd. (Tel Aviv, Israel). In return, Compugen will receive milestone payments and royalties based on the commercialization of its intellectual property.

The agreement couples DPC's ability to manufacture and market immunoassay-based products with Compugen's recent discoveries of a molecule linked to prostate-specific antigen (PSA-LM) and an hK2-linked molecule (K-LM). The two proteins are encoded by alternative mRNA splice variants of the genes for PSA and a related protein, human kallikrein 2 (hK2). PSA and human kallikrein 2 are closely related products of human kallikrein genes KLK3 and KLK2, respectively. Both proteins are secreted by the prostate and play important roles as biomarkers in the diagnosis of prostate cancer.

"This alliance is another strong validation of our continuing assertion that Compugen's unique computational biology research can result in the discovery of meaningful biologic information that would otherwise be extremely difficult to discover solely through experimentation,” said Mor Amitai, Ph.D., president and CEO of Compugen.





Related Links:
DPC
Compugen

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Hematology Consumables
Bioblood Devices
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Adobe Stock

Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy

Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read more

Molecular Diagnostics

view channel
Image: The Xpert Hemorrhagic Fever Panel test runs on Cepheid’s GeneXpert Dx systems (Photo courtesy of Cepheid)

WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response

The Democratic Republic of the Congo is confronting an Ebola Bundibugyo outbreak that the World Health Organization (WHO) designated a Public Health Emergency of International Concern on May 17, 2026.... Read more

Microbiology

view channel
Image Credit: Adobe Stock

Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.